It’s always good to be the leader. It’s even better if you can promise to stay out front.
Novartis proved that point again with a fresh batch of longterm data to back up its blockbuster IL-17A drug Cosentyx, which has a group of new rivals nipping at its heels.
Investigators for the pharma giant turned up at the Annual European Congress of Rheumatology in Madrid to offer evidence that 80% of ankylosing spondylitis patients achieved a key efficacy point at three years. A separate two-year post hoc analysis showed that more than half of all psoriatic arthritis patients on the drug also achieved a significant reduction in pain. And 28% were free of pain, a major outcome for a group that was universally experiencing moderate to severe pain.
Why is that particularly important?
With Eli Lilly fielding Taltz and Valeant pushing Siliq, Novartis wants to do everything it can to highlight the positives on this drug. J&J’s guselkumab is also on the way, boasting some impressive data on psoriasis, where Novartis got started close to two years ago.
“These data reconfirm that Cosentyx provides patients with long-lasting relief from the symptoms of ankylosing spondylitis and psoriatic arthritis, as well as now demonstrating rapid pain relief from psoriatic arthritis”, said Vas Narasimhan, global head of drug development and chief medical officer, Novartis.
The best place to read Endpoints News? In your inbox.
Full-text daily reports for those who discover, develop, and market drugs. Join 21,000+ biopharma pros who read Endpoints News by email every day.Free Subscription